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ARTICLE

Efficacy and Safety of Eluxadoline in Patients With
Irritable Bowel Syndrome With Diarrhea Who Report
Inadequate Symptom Control With Loperamide:
RELIEF Phase 4 Study
Darren M. Brenner, MD1, Gregory S. Sayuk, MD2,3, Catherine R. Gutman, PhD4, Esther Jo, MPH5, Steven J. R. Elmes, PhD4,
Louis W. C. Liu, MD, PhD6 and Brooks D. Cash, MD7
OBJECTIVES:

Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder with
limited effective treatment options. We evaluated the efficacy and safety of eluxadoline in
patients with IBS-D who reported inadequate symptom control with prior loperamide.

METHODS:

Three hundred forty-six adults with IBS-D (Rome III criteria) were randomly assigned to placebo or
eluxadoline 100 mg twice daily for 12 weeks. Patients recorded daily IBS-D symptoms, including worst
abdominal pain (WAP) and stool consistency (through Bristol Stool Scale). The primary endpoint was
proportion of composite responders, defined as patients who met daily composite response criteria
(‡40% WAP improvement and <5 Bristol Stool Scale score) for at least 50% of treatment days, and
recorded ‡60 days of diary entries over the 12-week period.

RESULTS:

Over 12 weeks, a significantly greater proportion of eluxadoline patients achieved the primary
composite responder endpoint compared to placebo (22.7% vs 10.3%, P 5 0.002), and component
endpoints of improvements in stool consistency (27.9% vs 16.7%, P 5 0.01) and WAP (43.6% vs
31.0%, P 5 0.02). Additionally, a greater proportion of eluxadoline patients met the composite
responder endpoint assessed at monthly intervals compared to placebo (weeks 1–4: 14.0% vs 6.9%,
P 5 0.03; weeks 5–8: 26.7% vs 14.9%, P 5 0.006; weeks 9–12: 30.8% vs 16.7%, P 5 0.002). Rates
of adverse events were comparable in both groups (37.4% vs 35.3%); no treatment-related serious
adverse event, cases of sphincter of Oddi spasm, or pancreatitis were reported.

DISCUSSION:

Eluxadoline appears safe and effective for treating IBS-D symptoms in patients with an intact
gallbladder reporting inadequate relief with prior loperamide use.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/B246, http://links.lww.com/AJG/B265, http://links.lww.com/AJG/B266, and
http://links.lww.com/AJG/B267

Am J Gastroenterol 2019;114:1502–1511. https://doi.org/10.14309/ajg.0000000000000327

INTRODUCTION
Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder, with an estimated global prevalence of
11% (1,2). IBS is characterized by regular abdominal pain associated with changes in stool frequency and/or consistency and is
subtyped based on the predominant stool pattern: IBS with
constipation, diarrhea (IBS-D), mixed, or unsubtyped. Of the
subtypes, IBS-D is the most common, comprising nearly 45% of
all IBS cases (3).

Eﬀective treatment options for IBS-D are limited, and patients
often resort to interventions based on relieving individual
symptoms. Typical initial therapeutic interventions include dietary and lifestyle modiﬁcations, as well as over-the-counter
antidiarrheals. Loperamide, a peripherally restricted m-opioid
receptor (m-OR) agonist that mechanistically decreases gut motility and increases ﬂuid reabsorption, is one of the most commonly used agents for the management of IBS-D (4,5) despite the
recent American College of Gastroenterology IBS Monograph
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strongly recommending against it as an IBS therapy (6). Loperamide is not indicated for long-term use and does not alleviate
abdominal pain or bloating (7–11). Therefore, there is considerable need for new and eﬀective treatments with favorable safety
proﬁles that hold the potential to provide sustained symptom
relief for patients with IBS-D.
Eluxadoline is a locally acting, mixed m-OR agonist, k-opioid
receptor agonist, and d-opioid receptor (d-OR) antagonist with
minimal oral bioavailability approved by the US Food and Drug
Administration (FDA) for the treatment of IBS-D (12). Owing
to its combined pharmacological proﬁle, eluxadoline reduces
gut motility consistent with its primary role as a m-OR agonist
and, due to its d-OR antagonism, decreases the potential for
medication-induced constipation. Importantly, eluxadoline was
also shown to improve abdominal pain in 2 randomized, multicenter, multinational, double-blind, placebo-controlled phase
3 studies (IBS-3001 and IBS-3002) conducted in more than
2,400 patients with IBS-D (13). These unique features distinguish eluxadoline from peripherally acting m-OR agonists such
as loperamide (14). The primary endpoint of the two phase 3
trials of eluxadoline was deﬁned by the simultaneous improvement in the daily worst abdominal pain (WAP) score by
$30% compared with baseline weekly average and a reduction
in the Bristol Stool Scale (BSS) to ,5 on at least 50% of days
within a 12-week treatment period (FDA endpoint) and a 26week treatment period (European Medicines Agency endpoint).
The 2 studies demonstrated that eluxadoline 100 mg twice daily
had signiﬁcantly greater composite responder rates as compared
with placebo.
Patient history of prior loperamide use was collected in both
phase 3 studies, and post-hoc analyses on the eﬃcacy of eluxadoline in patients previously treated with loperamide were
conducted (15). In total, 36% of all 2,400 patients with IBS-D in
these studies reported prior loperamide use, among whom 62%
self-reported inadequate symptom control. In the subpopulation of those not achieving adequate symptom control
with prior loperamide use, a signiﬁcantly greater proportion
were composite responders following treatment with eluxadoline as compared to placebo (15). However, this subgroup
analysis depended on patient recollection with varied durations
of prior loperamide use. Therefore, the present study was conducted to further evaluate the eﬃcacy, safety, and tolerability of
eluxadoline 100 mg twice daily in patients who reported inadequate IBS-D symptom control with loperamide in the preceding 12 months. It was anticipated that the ﬁndings from this
study would further our understanding on the utility of eluxadoline among patients with IBS-D self-reported as having experienced inadequate symptom relief with loperamide.

METHODS
Study design

This was a double-blinded, randomized, placebo-controlled,
prospective, multicenter, multinational phase 4 study in adult
patients with IBS-D (trial registration NCT02959983). The study
comprised a 1-week screening period in which patients were
assessed for eligibility, followed by a 3-week pretreatment period
during which patients completed electronic patient-reported
outcome (ePRO) diaries to record daily information regarding
their IBS-D symptoms and loperamide rescue medication use.
Following the pretreatment period, eligible patients who met the
study entry criteria related to ePRO diary compliance, stool

consistency (assessed by BSS), average WAP, and use of loperamide rescue medication were randomized through a central
randomization system to receive eluxadoline 100 mg or placebo
twice daily for 12 weeks. During the treatment period, patients
returned to the clinic for visits at weeks 4, 8, and 12 (end-oftreatment visit), and for a post-treatment follow-up study visit at
week 14. The total study duration was up to 18 weeks, with 7 site
visits for each patient. The study design is presented in Supplementary Figure 1 (see Supplementary Digital Content 1, http://
links.lww.com/AJG/B246).
Participants

Eligible patients were 18–80 years of age, with a diagnosis of
IBS-D per Rome III criteria (deﬁned as loose [mushy] or watery
stools $25% and hard or lumpy stools #25% of bowel movements), an average WAP score of .3.0 (on a scale from 0 [no
pain] to 10 [worst imaginable pain]) in the preceding 24 hours,
an average BSS score of $5.5 (on a scale of 1 [hard lumpy stool]
to 7 [entirely liquid stool]), and a BSS score of $5 in $5 days
during the week before randomization. Prospective patients
who met the above diagnostic criteria were prescreened based
on loperamide use in the preceding 12 months and self-reported
overall inadequate IBS symptom control with loperamide for
study inclusion. A follow-up questionnaire was administered,
which queried the patterns of medication usage (i.e., frequency,
duration, reason for stopping, and degree of satisfaction with
individual symptom relief including diarrhea, abdominal pain,
and improvement in bowel movement) among patients who
indicated that they managed their IBS-D using loperamide,
antidiarrheals other than loperamide, antidepressants, and
anticholinergics/antispasmodics. Patients were not allowed to use
loperamide within 14 days before randomization. Patients were also
required to complete the ePRO diary on at least 5 of the 7 days
during the week before randomization and at least 10 of the 14 days
during the 2-week pretreatment period before randomization. Key
exclusion criteria were patients with IBS with constipation, IBS with
mixed, or IBS with unsubtyped, history of inﬂammatory or
immune-mediated GI disorders, diverticulitis, pancreatitis, known
or suspected biliary duct obstruction, or sphincter of Oddi disease.
Patients without a gallbladder were excluded in line with the updated
US label (12). Patients with current or expected use of any narcotic
or opioid-containing agents (e.g., antidiarrheal medications [except
loperamide rescue medication after randomization] or opioid
analgesics), or those with a history of alcohol abuse, alcohol addiction, or consumption of .3 alcoholic beverages per day were also
excluded. Full eligibility criteria are included in the study protocol
(see Supplementary Digital Content 2, http://links.lww.com/AJG/
B265). The study protocol was approved and ﬁnalized before the
ﬁrst patient was screened, and written informed consent was
obtained from all participants before initiation of any study-related
activities.
Study outcomes and assessments

During the double-blind 12-week treatment period, patients
recorded daily IBS-D symptoms including stool consistency
(assessed through BSS), WAP, abdominal discomfort, abdominal
bloating, bowel movement frequency, number of episodes of
urgency in a day, number of episodes of fecal incontinence, and
loperamide rescue medication use, through the ePRO diary.
The primary eﬃcacy endpoint was the proportion of composite
responders, deﬁned as patients who met the daily composite
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response criteria (daily pain response: WAP score improvement by
$40% in the preceding 24 hours and daily stool consistency response: BSS score ,5 [or absence of bowel movement accompanied
by $40% WAP improvement compared to baseline]) for at least
50% of treatment days and had $60 days of diary entries over the
12-week treatment period. Patients with ,60 days of diary entries
were considered nonresponders for the primary eﬃcacy endpoint.
The 3 main secondary eﬃcacy endpoints were deﬁned as follows: (i) proportion of stool consistency responders (i.e., patients
who met the daily stool consistency for $50% of days with diary
entries over a certain time period, deﬁned for the full 12-week
treatment period [$60 days of diary entries for the full 12 weeks]
and each 4-week interval [.20 days of diary entries for each
4-week interval]); (ii) proportion of pain responders (i.e., patients
who met the daily pain response criteria for $50% of days with
diary entries over a certain time period, deﬁned for the full
12-week treatment period [$60 days of diary entries for the full
12 weeks] and each 4-week interval [.20 days of diary entries for
each 4-week interval]); (iii) proportion of monthly composite
responders (i.e., patients who met the daily composite response
criteria for .50% of days with diary entry for $20 days during
each 4-week interval [weeks 1–4, 5–8, and 9–12]). Patients with
,60 days of diary entry for the 12-week treatment period or ,20
days of diary entries for the 4-week intervals were considered
nonresponders for the secondary eﬃcacy endpoints.
Composite responder data were further analyzed by weekly
responders for each week up to week 12 with responders deﬁned
in 2 ways. For deﬁnition #1, weekly composite responders were
deﬁned as daily composite responders on $4 days for a week
(daily composite responder: $40% WAP improvement and ,5
BSS score [or absence of bowel movement accompanied by $40%
WAP improvement compared to baseline]). For deﬁnition #2,
weekly composite responders were deﬁned as patients with
weekly average WAP improvement of $40% from average WAP
of the baseline week and with $50% reduction in the days of BSS
score 6/7 for a study week compared with days of BSS score 6/7
during the baseline week. An analysis was also performed using
$6-week responders, wherein patients were required to meet the
2 weekly composite responder deﬁnitions deﬁned above for at
least 6 weeks over the 12-week treatment period. Safety and tolerability assessed the incidence of treatment-emergent adverse
events (TEAEs). Additional endpoints are described in the study
protocol and statistical analysis plan included in the Supplementary Materials (see Study Protocol, Supplementary Digital Content
2, http://links.lww.com/AJG/B265 and Statistical Analysis, Supplementary Digital Content 3, http://links.lww.com/AJG/B266).
Statistical analyses

The trial was designed with 90% power to detect the diﬀerence
of the primary eﬃcacy endpoint response for eluxadoline vs
placebo using a 2-sided x2 test at a signiﬁcance level of 0.05.
Similar to the primary endpoint, the secondary eﬃcacy endpoints
were analyzed using the number and percentage of the corresponding responders with P-values from x2 test. No adjustment
for the multiplicity of endpoints was performed.
Diary compliance was summarized by compliance categories
(,60 vs .60 days) during the full 12-week treatment period
(;84 days) or ,20 vs .20 days for the 4-week intervals, each
corresponding to at least 70% compliance. For partial diary
entries, compliance was aﬃrmative if either WAP score and BSS
score or WAP score and bowel movement frequency of zero were
The American Journal of GASTROENTEROLOGY

completed. For patients who met the criteria of the minimum of
4 days of diary entry, missing diary entries were imputed using the
last observation carried forward method, the percent reduction
calculation used the imputed data. Safety data were summarized
using descriptive statistics. Adverse events were coded using the
Medical Dictionary for Regulatory Activities (MedDRA, v20.0).
Evaluation of eﬃcacy and patient demographics was based on
the intent-to-treat population, which included all randomized
patients. For the intent-to-treat population, patients were analyzed according to their randomization assignment, regardless of
the actual treatment received. Evaluation of safety endpoints was
conducted using the safety population, which included all enrolled patients who received at least one dose of study drug.
For the safety population, patients were grouped and analyzed
according to the treatment they actually received. Additional
details related to statistical analysis are described in the study
protocol and statistical analysis plan included in the Supplementary Materials (see Study Protocol, Supplementary Digital
Content 2, http://links.lww.com/AJG/B265 and Statistical Analysis, Supplementary Digital Content 3, http://links.lww.com/
AJG/B266).
Data availability

Data reported in this manuscript are available within the article
and its supplementary materials. Additional data from the RELIEF
study may be requested at http://www.allerganclinicaltrials.com/
PatientDataRequest.htm.

RESULTS
Patient disposition

The study was conducted from November 2016 to January 2018
in 82 study sites across the United States and Canada. Of the 660
screened for eligibility, 346 patients were randomized to either
placebo (n 5 174) or eluxadoline (n 5 172), and 295 (85.3%)
completed the trial (see Figure 2, Supplementary Digital Content 1,
http://links.lww.com/AJG/B246). Baseline characteristics among the
patients were similar between the placebo and eluxadoline groups.
The mean age was 44 years, 70% were women, and the median time
since IBS-D diagnosis was 6 years. Overall, baseline IBS-D symptoms, including WAP, stool consistency, and patterns of bowel
movements, were also similar between the 2 groups (Table 1).
IBS-D treatment before randomization

Previous treatment for IBS-D was balanced between the 2 groups.
Use of antidiarrheal medications other than loperamide was
reported by 27 (15.5%) patients in the placebo group and 23
(13.4%) in the eluxadoline group (see Table 1, Supplementary
Digital Content 1, http://links.lww.com/AJG/B246). In addition,
patients also reported managing their IBS-D using antidepressants,
anticholinergics/antispasmodics, and in fact, .60% of patients
tried at least one additional method, including lifestyle changes.
For most patients (approximately 85%), loperamide was taken on
an as-needed basis, while approximately 11% reported daily
loperamide use (Table 2). Duration of loperamide use varied
among the patients, with 80 (46.5%) in the placebo group and
67 (39.4%) in the eluxadoline group having taken loperamide
for longer than 1 year. At randomization, 40 (23.3%) patients in
placebo as compared to 55 (32.4%) patients in the eluxadoline
group reported continued loperamide use, whereas .40% of
patients in each group reported that they had stopped taking
loperamide due to lack of improvement in their abdominal and
VOLUME 114 | SEPTEMBER 2019 www.amjgastro.com
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Placebo
(n 5 174)

Eluxadoline
(n 5 172)

Age, mean yr (SD)

43.9 (14.2)

43.8 (13.9)

Women, n (%)

119 (68.4)

124 (72.1)

White, n (%)

141 (81.0)

144 (83.7)

Not Hispanic or Latino, n (%)

133 (76.4)

139 (80.8)

Weight, mean kg (SD)

86.3 (24.7)

84.1 (23.7)

Height, mean cm (SD)

168.6 (9.6)

167.7 (10.6)

BMI, mean kg/m2 (SD)

30.4 (8.3)

29.9 (8.0)

Duration of IBS-D, median yr
(Q1, Q3)

7.0 (3.0, 14.7)

6.0 (2.6, 14.0)

Weekly average of daily worst
abdominal pain, mean (SD)

6.0 (1.6)

6.3 (1.5)

Stool consistency, BSS, mean (SD)

6.2 (0.4)

6.2 (0.4)

Weekly average of daily abdominal
discomfort, mean (SD)

6.2 (1.6)

6.4 (1.5)

Weekly average of daily abdominal
bloating, mean (SD)

6.2 (1.9)

6.5 (1.6)

Weekly average of daily number of
bowel movement frequency,
mean (SD)

4.2 (2.3)

4.0 (1.8)

Weekly average of daily number of
urgency episodes, mean (SD)

2.9 (2.4)

2.7 (1.8)

Weekly average of daily number of
bowel incontinence episodes, mean
(SD)

1.1 (2.0)

1.2 (2.0)

Weekly average of incontinence-free
days, mean (SD)

5.3 (1.8)

5.2 (1.8)

Diary compliance, $60 entries within
84 days, n (%)

127 (73.4)

131 (76.6)

Diary compliance based on double-blind treatment period (84 days) using the
safety population.
P-values were not significant (P . 0.05) for each parameter; P-values for
continuous variables were based on t-test; analysis for categorical variables
were based on x2 test.
BMI, body mass index; BSS, Bristol Stool Scale; IBS-D, irritable bowel syndrome
with diarrhea; Q1, first quartile; Q3, third quartile.

bowel symptoms. Although all patients self-reported overall inadequate symptom relief with prior loperamide use in line with
protocol requirement, ;55% and ;42% of patients in each treatment group indicated varying degrees of satisfaction (ranging
from “a little satisﬁed” to “very satisﬁed”) with individual symptom
relief of diarrheal and abdominal pain with loperamide, respectively. Conversely, ;45% and ;58% were “not at all satisﬁed”
with the degree of individual diarrheal and abdominal pain relief,
respectively, from prior loperamide use. Similarly, ;55% of
patients in each group reported varied satisfaction with decreased
urgency and improvement in bowel movement with prior loperamide use, whereas ;45% reported lack of satisfaction. Except for
the rates of continued loperamide use, patterns of loperamide usage
in the 12 months preceding randomization were balanced between
the 2 groups (Table 2).

Primary endpoint

A statistically signiﬁcantly greater proportion of eluxadolinetreated patients achieved the primary composite responder
endpoint compared with patients treated with placebo (eluxadoline: 22.7% [39/172], placebo: 10.3% [18/174]; P 5 0.002)
(Figure 1a). Analysis of the monthly composite endpoint responder population showed that a greater proportion of patients
treated with eluxadoline met the composite responder endpoint
during each 4-week interval compared to placebo-treated patients
(weeks 1–4: 14.0% vs 6.9%, P 5 0.03; weeks 5–8: 26.7% vs 14.9%,
P 5 0.006; weeks 9–12: 30.8% vs 16.7%, P 5 0.002) (Figure 1a).
Separation of response in the daily composite responders was
observed within the initial 14 days of treatment that favored
eluxadoline and persisted throughout the study (Figure 1c).
A post-hoc analysis of daily composite endpoint responders
was performed based on the primary composite endpoint criteria
previously used in the phase 3 studies and consistent with FDA
guidance for the design and completion of IBS-D trials (daily
$30% improvement in WAP and daily stool consistency response [BSS score ,5 or the absence of a bowel movement if
accompanied by $30% improvement in WAP]) (16). A signiﬁcantly greater proportion of patients treated with eluxadoline met
this alternate composite responder endpoint during each of the
4-week intervals and the overall 12-week period as compared to
patients treated with placebo (weeks 1–12: 26.2% vs 13.8%, P 5
0.004; weeks 1–4: 19.2% vs 8.6%, P 5 0.005; weeks 5–8: 29.7% vs
18.4%, P 5 0.013; weeks 9–12: 31.4% vs 20.1%, P 5 0.016)
(Figure 1b).
Key secondary efficacy outcomes

A prespeciﬁed analysis of composite responder data was performed for weekly responders for each week up to week 12 with
responders deﬁned in 2 ways (see METHODS section for the
deﬁnitions). During the study, a greater proportion of patients
treated with eluxadoline met the criteria for weekly composite
responders by both deﬁnitions as compared to the placebo group
at weeks 4, 5, 6, 7, 9, 11, and 12 (see Figure 3, Supplementary
Digital Content 1, http://links.lww.com/AJG/B246). Furthermore, as compared to the placebo group, treatment with eluxadoline resulted in a signiﬁcantly higher proportion of $6-week
composite responders for the analyzed weeks 1–6 (see Figure 4,
Supplementary Digital Content 1, http://links.lww.com/AJG/B246)
and weeks 1–12 (Figure 2) periods during the 12-week treatment
period for both responder deﬁnitions.
A signiﬁcantly greater proportion of patients treated with
eluxadoline met the abdominal pain response endpoint over the
12-week period as compared with placebo (43.6% [75/172] vs
31.0% [54/174]; P 5 0.02) (Figure 3a). During each 4-week interval, treatment with eluxadoline resulted in improvements in
WAP response over placebo (weeks 1–4: 30.2% vs 25.9%, P 5
0.38; weeks 5–8: 45.9% vs 31.6%, P 5 0.005; weeks 9–12: 44.8% vs
35.1%, P 5 0.06). Abdominal pain responder data were further
analyzed for patients who met daily 30% and 50% pain response
criteria for $50% of days with diary entries over either the full
12-week treatment period or the three 4-week intervals. Treatment with eluxadoline resulted in a greater proportion of pain
responders with both 30% and 50% improvement in WAP as
compared with placebo during the overall 12-week treatment
period and over the 4-week intervals (Figures 3b,c). In addition,
a signiﬁcantly greater proportion of patients treated with eluxadoline over the 12-week period were stool consistency
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Table 2. Patterns of loperamide usage in the 12 months preceding randomization

Question

Response

Placebo (n 5 174)
n (%)

Eluxadoline (n 5 172)
n (%)

Patients who took loperamide in the
preceding 12 monthsa

Yes

172 (98.9)

170 (98.8)

Frequency
“How do (or did) you use this medication?”

Daily
As needed
Other

19 (11.0)
150 (87.2)
3 (1.7)

23 (13.5)
144 (84.7)
3 (1.8)

Duration
“How long have you taken (or did you take)
this medication?”

Less than 1 week
Greater than 1 week but less than 1 month
Greater than 1 month but less than 3 months
Greater than 3 months but less than 6 months
Greater than 6 months but less than 1 year
Greater than 1 year

19 (11.0)
21 (12.2)
13 (7.6)
19 (11.0)
20 (11.6)
80 (46.5)

33 (19.4)
20 (11.8)
17 (10.0)
17 (10.0)
16 (9.4)
67 (39.4)

Reason for stopping loperamide
“If you stopped taking this medication, what
was the reason?” (more than one answer was
allowed)

Not applicable (currently taking loperamide)
It did not improve my abdominal symptoms
It did not improve my bowel symptoms
I experienced side effect
It costs too much
Other

40 (23.3)
74 (43.0)
78 (45.3)
8 (4.7)
5 (2.9)
5 (2.9)

55 (32.4)
67 (39.4)
77 (45.3)
8 (4.7)
5 (2.9)
7 (4.1)

Satisfaction with diarrheal relief
“Overall, how satisfied are (or were) you with
the medication’s ability to relieve your
diarrhea?”

Not at all satisfied
A little satisfied
Moderately satisfied
Quite satisfied
Very satisfied

75 (43.6)
61 (35.5)
29 (16.9)
5 (2.9)
2 (1.2)

78 (45.9)
64 (37.6)
22 (12.9)
6 (3.5)
0

Satisfaction with abdominal pain relief
“Overall, how satisfied are (or were) you with
the medication’s ability to relieve your
abdominal pain?”

Not at all satisfied
A little satisfied
Moderately satisfied
Quite satisfied
Very satisfied

101 (58.7)
48 (27.9)
20 (11.6)
1 (0.6)
2 (1.2)

99 (58.2)
54 (31.8)
14 (8.2)
3 (1.8)
0

Satisfaction with improvements in bowel
movements
“Overall, how satisfied are (or were) you with
the medication’s ability to decrease the
number of times you experienced urgency in
relation to your bowel movements (sudden,
almost irresistible need to have a bowel
movement)?”

Not at all satisfied
A little satisfied
Moderately satisfied
Quite satisfied
Very satisfied

80 (46.5)
55 (32.0)
30 (17.4)
5 (2.9)
2 (1.2)

75 (44.1)
62 (36.5)
27 (15.9)
5 (2.9)
1 (0.6)

a

A database entry error resulted in the erroneous notation that 2 patients in each group did not take loperamide before study enrollment. The affected sites were queried,
and study questionnaires confirmed that all 4 patients took loperamide in the preceding 12 months as required by the inclusion criteria; however, the error was left as
recorded since correction of this discrepancy would have required retroactive correction of source data.

responders as compared with placebo (27.9% [48/172] vs 16.7%
[29/174]; P 5 0.01) (Figure 3d). During each of the 4-week
intervals, greater improvements in stool consistency response
were observed with eluxadoline as compared to placebo. Collectively, these data demonstrated greater symptom improvement in key secondary endpoints throughout the 12-week
treatment period with eluxadoline as compared to placebo. A
summary of key eﬃcacy endpoints is provided in Supplementary Table 2 (see Supplementary Digital Content 1, http://links.lww.
com/AJG/B246).
Safety and tolerability

A total of 112 TEAEs were reported in the placebo group and 124
TEAEs in the eluxadoline group. The proportion of patients
reporting at least one TEAE was comparable with eluxadoline
(37.4% [64/171]) and placebo (35.3% [61/173]) (Table 3). Higher
The American Journal of GASTROENTEROLOGY

rates of treatment-related TEAEs were reported in the eluxadoline group (15.8% [27/171]) as compared to the placebo group
(5.8% [10/173]). TEAEs leading to premature treatment discontinuations and study discontinuations were higher in the
eluxadoline group (5.8% [10/171] and 2.9% [5/171], respectively)
compared to the placebo group (1.7% [3/173] and 0.6% [1/171],
respectively), whereas a higher rate of severe TEAEs was reported
in the placebo group (2.9% [5/173]) as compared to the eluxadoline group (1.8% [3/171] [Table 3]). Three patients in the
placebo group (1.7%) and 1 patient in the eluxadoline group
(0.6%) experienced serious TEAEs (summarized in Table 3,
Supplementary Digital Content 1, http://links.lww.com/AJG/
B246), none of which were related to treatment.
Gastrointestinal AEs (GIAEs) were the most common
treatment-emergent events, with a higher rate reported in the
eluxadoline group (17.0% [29/171]) as compared to the placebo
VOLUME 114 | SEPTEMBER 2019 www.amjgastro.com
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Figure 1. Analyses of composite responders. (a) Composite endpoint of daily responders (i.e., patients who meet daily composite response criteria on
$50% of days, defined as $40% improvement in WAP compared with baseline and BSS score ,5 [or the absence of a bowel movement if accompanied
by $40% improvement in WAP]). Monthly composite responders are patients who met the daily composite response criteria on $50% of days and had
a minimum of 20 days of diary entries for each 4-week interval. (b) A post-hoc analysis of composite responders defined at $30% improvement in WAP
compared with baseline pain and daily stool consistency response. For both analyses, any patient with fewer than 20 days of diary entries for the 4-week
interval was considered as a nonresponder. (c) Daily composite responders ($40% WAP improvement and BSS score ,5) over time. BSS, Bristol Stool
Scale; WAP, worst abdominal pain. P-values are based on x2 test.

group (6.4% [11/173]). Most GIAEs were mild-to-moderate in
intensity, with 3 severe events reported in the eluxadoline group
(Table 3). Of these, 1 event (pancreatic mass) was a serious AE,
which was unrelated to treatment, from which the patient recovered and the drug was withdrawn. Of all TEAEs, nausea was
the most common event at 5.8% (10/171) in the eluxadoline
group as compared to the 2.9% (5/173) reported in the placebo

group. A summary of TEAEs $2% in any group is provided by
preferred term in Table 3. No episodes of pancreatitis or sphincter
of Oddi spasm were reported in the study.

DISCUSSION
Loperamide, a m-OR agonist that reduces the frequency of
bowel movements and improves stool consistency, is

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology
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Figure 2. Weekly composite responder during the 12-week treatment
period, and for at least 6 weeks out of 12 weeks from weeks 1–12 by
2 definitions. Definition #1 5 weekly composite responder is defined
as daily composite responder on $4 days for a week. Daily composite
responder 5 WAP improvement by $40% compared with baseline and
BSS score ,5 (or the absence of bowel movement if accompanied by
$40% improvement in WAP) compared to baseline. Definition #2 5
weekly composite responder is defined as patients with weekly average
WAP improvement of $40% from average WAP of the baseline week
and with $50% reduction in the days of BSS score 6/7 for a week comparing with days of BSS score 6/7 during the baseline week. BSS, Bristol
Stool Scale; WAP, worst abdominal pain. P-values are based on x2 test.

frequently used as a ﬁrst-line agent for IBS-D. However,
studies have revealed that loperamide is ineﬀective in treating
the abdominal symptoms of IBS (1,7–11). Use of IBS treatments with limited eﬃcacy may result in additional medical
visits, investigations, and adoption of other therapeutic
approaches, including agents with minimal evidence of beneﬁt
(17,18). Such “treatment-failure” patients are challenging to
treat, as diminishing returns often are experienced with additional therapeutic interventions; moreover, these patients
frequently suﬀer from higher psychological and nonpain
comorbidities, further complicating their treatment (19). In
the present study, most patients reported use of other antidiarrheals, antidepressants, anticholinergics, and lifestyle
modiﬁcations before enrollment, indicating a clear need for
safe and eﬀective agents that achieve sustained global relief of
IBS-D earlier and more eﬃcaciously.
In this multicenter, randomized, controlled phase 4 study
of eluxadoline vs placebo in patients with IBS-D who reported
inadequate symptom control with loperamide in the 12
months preceding the study, we found that a signiﬁcantly
greater proportion of patients receiving eluxadoline achieved
daily improvement in abdominal pain ($40%) and stool
consistency (,5 BSS score, or absence of bowel movement)
for at least 50% of treatment days. These improvements were
observed within the initial 4 weeks of treatment and sustained
until the end of the study. Similarly, the monthly composite
responder endpoints were met by a higher proportion of
The American Journal of GASTROENTEROLOGY

eluxadoline-treated patients than those who received placebo.
A higher percentage of patients receiving eluxadoline also
achieved the secondary endpoints of improvements in stool
consistency and abdominal pain compared to placebo.
In the two phase 3 studies (IBS-3001 [52-week treatment]
and IBS-3002 [26-week treatment]) evaluating the safety
and eﬃcacy of eluxadoline, the primary composite endpoint
was deﬁned as a concurrent $30% improvement in daily
abdominal pain score compared with baseline and a BSS score
,5 on at least 50% of days within a 12-week treatment period
(FDA endpoint) and a 26-week treatment period (European
Medicines Agency endpoint) (13). In both studies, eluxadoline demonstrated signiﬁcantly greater composite responder
rates compared to placebo over the respective treatment
periods. Subsequently, a retrospective analysis of these phase
3 data was performed to evaluate the eﬃcacy of eluxadoline in
patients who had been previously treated with loperamide
(15). Over one-third of patients (873/2,428) in the phase
3 studies reported prior loperamide use, among whom nearly
60% (538/873) self-reported inadequate loperamide symptom control; in this subpopulation, a signiﬁcantly greater
proportion were composite responders following treatment
with 100 mg of eluxadoline compared to placebo over 12
weeks (15). Similar to the retrospective analysis of phase
3 trial data, a signiﬁcantly greater proportion of loperamideunresponsive patients in the current prospective study
met the responder criteria with eluxadoline as compared to
placebo over 12 weeks of treatment. Notably, in the current
trial, a more stringent deﬁnition was set for daily clinical
responders as a patient with IBS-D had to achieve $40%
improvement in WAP. Despite this more stringent endpoint,
the results herein are similar to those observed in the phase
3 trials.
We also performed a post-hoc analysis using the phase 3
study primary endpoint criteria ($30% WAP improvement
and a reduction to ,5 in the BSS score) and found that a signiﬁcantly higher proportion of eluxadoline-treated patients
achieved this FDA-mandated composite responder criteria
compared to placebo over 12 weeks of treatment. Moreover,
a similar treatment eﬀect on the 12-week primary endpoint
was also achieved for the phase 3 subpopulation who reported
lack of adequate symptom control with prior loperamide
use at 12 and 26 weeks (15). Therefore, the reproducibility of
the phase 3 analysis in the current study further
substantiates the positive treatment eﬀect of eluxadoline on
the composite endpoint and in the context of previous
loperamide failure.
IBS and its range of symptoms are often diﬃcult to treat;
however, these collective data show favorable results in the
patient population who have failed loperamide, a treatment
often used as standard of care. The positive outcomes of this
study in a real-world setting suggest that eluxadoline may be
an option for those who have previously used loperamide.
Abdominal pain, a major clinical feature of IBS, is often the
most challenging to treat and is closely linked to disease severity (20–22). Analysis of a $40% improvement in abdominal pain threshold over 12 weeks demonstrated a signiﬁcantly
higher responder rate in the eluxadoline group compared to
placebo. Signiﬁcant diﬀerences were maintained when the
data were imputed using $30% abdominal pain improvement
criteria as was used in the phase 3 studies, as well as for the
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Figure 3. Analysis of pain and stool consistency responders. (a) Monthly pain responders (i.e., patients who met the daily pain response criteria for $50% of
days with diary entries over a certain time period, defined for the full 12-week treatment period [$60 days of diary entries for the full 12 weeks] and each
4-week interval [.20 days of diary entries for each 4-week interval] as $40% improvement in WAP compared with baseline). Analysis of responders who
met the daily (b) 30% and (c) 50% improvement in WAP. (d) Analysis of monthly stool consistency responders (i.e., patients who met the daily stool
consistency for $50% of days with diary entries over a certain time period, defined for the full 12-week treatment period [$60 days of diary entries for
the full 12 weeks] and each 4-week interval [.20 days of diary entries for each 4-week interval]) compared with baseline. WAP, worst abdominal pain.
P-values are based on x2 test.

stricter $50% abdominal pain improvement pain response.
These data are generally in line with the phase 3 studies, which
showed that the $30% abdominal pain response component
showed an improvement, although not statistically signiﬁcant, for eluxadoline over placebo in the overall population.
The experience of abdominal pain in IBS is complex and is
inﬂuenced by a multitude of patient factors, including psychological comorbidity, previous abuse experiences, and non-

GI pain comorbidities. Additionally, environmental factors
including diet and stress can further modulate these symptom
experiences (23). Data from the current study showed signiﬁcant improvements in abdominal pain across a wide range
of subjective pain endpoints. Stool consistency response was
also similar to the primary composite rate over the 12-week
treatment period, and collectively, our data suggest that the
overall response of the composite endpoint was driven by

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology
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Table 3. Summary of treatment-emergent adverse events

Total number of TEAEs

Placebo
(n 5 173)
n (%)

Eluxadoline
(n 5 171)
n (%)

112

124

Patients with at least one TEAE

61 (35.3)

64 (37.4)

Treatment-related TEAE

10 (5.8)

27 (15.8)

Treatment discontinuations due to a TEAE

3 (1.7)

10 (5.8)

Study discontinuations due to a TEAE

1 (0.6)

5 (2.9)

Severe TEAE

5 (2.9)

3 (1.8)

Treatment-emergent serious AE

3 (1.7)

1 (0.6)

11 (6.4)

29 (17.0)

0

3 (1.8)

GIAEs
Severe
Vomiting

0

1 (0.6)

Abdominal distension

0

1 (0.6)

0

1 (0.6)

Moderate

Pancreatic mass

6 (3.5)

10 (5.8)

Mild

5 (2.9)

16 (9.4)

Nausea

5 (2.9)

10 (5.8)

Constipation

2 (1.2)

8 (4.7)

Nasopharyngitis

4 (2.3)

6 (3.5)

Influenza

4 (2.3)

5 (2.9)

TEAEs $2% in any group

Sinusitis

2 (1.2)

5 (2.9)

Headache

1 (0.6)

5 (2.9)

Upper respiratory tract infection

The most common TEAEs in the study were GI, indicative
of the local (GI) pharmacological eﬀects of eluxadoline.
GIAEs, including nausea, constipation, abdominal pain, and
vomiting, were reported more frequently in the eluxadoline
than the placebo group. Most GIAEs in the present study were
mild or moderate in intensity. Three severe events were
reported in the eluxadoline group, including vomiting, abdominal distension, and pancreatic mass, which were adjudicated as unrelated to eluxadoline. The single serious AE
reported in the eluxadoline cohort was a pancreatic mass in
a patient with a history of chronic alcohol consumption. This
was assessed by investigators as unrelated to treatment, but
treatment was withdrawn, and the pancreatic mass resolved
without sequelae. It is noteworthy that no cases of pancreatitis
or sphincter of Oddi spasm were reported in the present
study.
In summary, results of the current study demonstrate
positive treatment beneﬁts for eluxadoline over placebo in
patients with IBS-D reporting inadequate symptom relief
from loperamide, based on improvements in both abdominal
pain and stool consistency, the cardinal symptoms of IBS.
Moreover, the safety proﬁle of eluxadoline was comparable to
placebo, with no new safety concerns identiﬁed. We conclude
that this study prospectively validates previous ﬁndings revealing eluxadoline to be a safe, eﬀective IBS-D treatment in
patients reporting inadequate symptom relief with prior
loperamide use.
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Pancreatitis episodes

0

0

Sphincter of Oddi spasm

0

0

Deaths

0

0

TEAE is defined as any AE with a start date that is on or after the start date of
study medication, or any preexisting AE worsened either in intensity or
frequency after taking the first dose of the study medication. Serious AEs
were classified based on seriousness (i.e., if it resulted in death, was lifethreatening, resulted in inpatient hospitalization or prolongation of
existing hospitalization, was persistent or caused significant disability/
incapacity, or resulted in a congenital anomaly/birth defect). Severity of
AEs was based on intensity (i.e., mild, moderate, severe, or not applicable
if it cannot be graded) and how it impacted usual activity.
AE, adverse event; GIAE, gastrointestinal AE; TEAE, treatment-emergent
adverse event.

signiﬁcantly higher response in stool consistency in the earlyto-mid timepoints and by signiﬁcant improvements in abdominal pain in the mid-to-later timepoints of the trial. The
mechanistic basis for these observed diﬀerences with the
mixed m-OR agonist eluxadoline has not been fully elucidated
but are presumed related to the combined k-opioid receptor
agonist and d-OR antagonist characteristics unique to this
agent.
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Study Highlights
WHAT IS KNOWN

3 Eluxadoline is an FDA-approved therapy for the treatment of
IBS-D.

3 In post-hoc analyses of phase 3 clinical trials, patients failing
to experience improvements in their IBS symptoms from
loperamide appeared to derive symptomatic benefits from
eluxadoline.

WHAT IS NEW HERE

3 Eluxadoline improves IBS-D symptoms in individuals

subjectively reporting inadequate responses to loperamide.

3 Eluxadoline improves both pain and bowel functions in

individuals reporting inadequate responses to loperamide.

3 In a population of individuals with IBS-D with an intact
gallbladder, no events of sphincter of Oddi spasm or
pancreatitis occurred while taking eluxadoline.
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